175 related articles for article (PubMed ID: 24830357)
1. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.
Grothey A; Flick ED; Cohn AL; Bekaii-Saab TS; Bendell JC; Kozloff M; Roach N; Mun Y; Fish S; Hurwitz HI
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):726-34. PubMed ID: 24830357
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.
Hurwitz HI; Bekaii-Saab TS; Bendell JC; Cohn AL; Kozloff M; Roach N; Mun Y; Fish S; Flick ED; Grothey A;
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):323-32. PubMed ID: 24686090
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of bevacizumab exposure beyond disease progression in patients with non-small-cell lung cancer: analyses of the ARIES observational cohort study.
Leon L; Kosty M; Jahanzeb M; Spigel D; Wozniak AJ; Brahmer J; Fish S; Flick ED; Hazard SJ; Lynch TJ
Pharmacoepidemiol Drug Saf; 2016 May; 25(5):569-77. PubMed ID: 26748833
[TBL] [Abstract][Full Text] [Related]
5. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology.
Cartwright TH; Yim YM; Yu E; Chung H; Halm M; Forsyth M
Clin Colorectal Cancer; 2012 Dec; 11(4):238-46. PubMed ID: 22658457
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.
Kabbinavar FF; Flynn PJ; Kozloff M; Ashby MA; Sing A; Barr CE; Grothey A
Eur J Cancer; 2012 May; 48(8):1126-32. PubMed ID: 22424880
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
8. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
Budai B; Nagy T; Láng I; Hitre E
Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
Tsutsumi S; Ishibashi K; Uchida N; Ojima H; Hosouchi Y; Yashuda N; Kigure W; Yamauchi S; Asao T; Ishida H; Kuwano H
Oncology; 2012; 83(3):151-7. PubMed ID: 22889925
[TBL] [Abstract][Full Text] [Related]
10. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
11. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
12. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens CC; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S;
Lancet Oncol; 2013 Jan; 14(1):29-37. PubMed ID: 23168366
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study.
Kozloff MF; Berlin J; Flynn PJ; Kabbinavar F; Ashby M; Dong W; Sing AP; Grothey A
Oncology; 2010; 78(5-6):329-39. PubMed ID: 20733336
[TBL] [Abstract][Full Text] [Related]
14. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
Yang H; Yu AP; Wu EQ; Yim YM; Yu E
J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
[TBL] [Abstract][Full Text] [Related]
15. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
[TBL] [Abstract][Full Text] [Related]
16. Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery.
Shitara K; Matsuo K; Kondo C; Takahari D; Ura T; Inaba Y; Yamaura H; Sato Y; Kato M; Kanemitsu Y; Komori K; Ishiguro S; Sano T; Shimizu Y; Muro K
Oncology; 2011; 81(3-4):167-74. PubMed ID: 22057124
[TBL] [Abstract][Full Text] [Related]
17. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.
Kiss I; Bortlicek Z; Melichar B; Poprach A; Halamkova J; Vyzula R; Dusek L; Buchler T
Anticancer Res; 2014 Feb; 34(2):949-54. PubMed ID: 24511038
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
Whyte S; Pandor A; Stevenson M; Rees A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of chemotherapy combined with bevacizumab for metastatic colorectal cancer].
Momoi A; Motomura S; Hashimoto C; Takasaki H; Takemura S; Takagi S; Akaike M
Gan To Kagaku Ryoho; 2011 Jan; 38(1):79-83. PubMed ID: 21368462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
